Download File - JOHN J. HADDAD, Ph.D.

108 Luptrawan et al.
66. Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting: from immunosurveillance
to tumor escape. Nat Immunol 2002; 3:991–998.
67. Nair S, Boczkowski D, Moeller B, et al. Synergy between tumor immunotherapy and
antiangiogenic therapy. Blood 2003; 102:964–971.
68. Liu G, Ying H, Zeng G, et al. HER-2, gp100, and MAGE-1 are expressed in human
glioblastoma and recognized by cytotoxic T cells. Cancer Res 2004; 64:4980–4986.
69. Nowak AK, Robinson BW, Lake RA. Synergy between chemotherapy and immunotherapy
in the treatment of established murine solid tumors. Cancer Res 2003;
63:4490–4496.
70. Gribben JG, Ryan DP, Boyajian R, et al. Unexpected association between induction
of immunity to the universal tumor antigen CYP1B1 and response to next therapy.
Clin Cancer Res 2005; 11:4430–4436.
71. Liu G, Black KL, Yu JS. Sensitization of malignant glioma to chemotherapy through
dendritic cell vaccination. Expert Rev Vaccines 2006; 5:233–247.
72. Ehtesham M, Yuan X, Kabos P, et al. Glioma tropic neural stem cells consist of
astrocytic precursors and their migratory capacity is mediated by CXCR4. Neoplasia
2004; 6:287–293.
73. Yuan X, Curtin J, Xiong Y, et al. Isolation of cancer stem cells from adult glioblastoma
multiforme. Oncogene 2004; 23:9392–9400.
74. Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating
cells. Nature 2004; 432:396–401.
75. Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human
brain tumors. Cancer Res 2003; 63:5821–5828.
76. Hemmati HD, Nakano I, Lazareff JA, et al. Cancerous stem cells can arise from
pediatric brain tumors. Proc Natl Acad Sci USA 2003; 100:15178–15183.
77. Salmaggi A, Boiardi A, Gelati M, et al. Glioblastoma-derived tumorospheres identify
a population of tumor stem-like cells with angiogenic potential and enhanced multidrug
resistance phenotype. Glia 2006; 54:850–860.
78. Liu G, Yuan X, Zeng Z, et al. Analysis of gene expression and chemoresistance of
CD133þ cancer stem cells in glioblastoma. Mol Cancer 2006; 5:67.
79. Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by
preferential activation of the DNA damage response. Nature 2006; 444:756–760.
80. Pellegatta S, Poliani PL, Corno D, et al. Neurospheres enriched in cancer stem-like
cells are highly effective in eliciting a dendritic cell-mediated immune response
against malignant gliomas. Cancer Res 2006; 66:10247–10252.
81. Tunici P, Irvin D, Liu G, et al. Brain tumor stem cells: new targets for clinical
treatments? Neurosurg Focus 2006; 20:E27.
82. Lake RA, Robinson BW. Immunotherapy and chemotherapy: a practical partnership.
Nat Rev Cancer 2005; 5:397–405.
83. Emens LA, Jaffee EM. Leveraging the activity of tumor vaccines with cytotoxic
chemotherapy. Cancer Res 2005; 65:8059–8064.
84. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic
relevance. Nat Rev Cancer 2005; 5:263–274.
85. Akasaki Y, Liu G, Chung NH, et al. Induction of a CD4þ T regulatory type 1 response
by cyclooxygenase-2-overexpressing glioma. J Immunol 2004; 173:4352–4359.
86. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond
current vaccines. Nat Med 2004; 10:909–915.